Quick preview

This regulatory briefing, reviewed on 1 November 2026, explains how to assess an import rather than announcing a blanket new peptide rule. It separates REACH registration from cosmetic-product safety, distinguishes a substance from a preparation, and follows the importer or only-representative role through tonnage and document checks. RAWESS peptide pages provide concrete examples of the identity and composition questions; they do not prove registration coverage, exemption or permission to import.

Requirements: define the import before discussing compliance

Treat this as an assessment briefing, not a new-law announcement

A calendar year in a headline is not evidence of a new legal obligation. This article uses the identified REACH and cosmetics provisions to explain the checks a buyer should perform as of the editorial review date. It does not assert that all cosmetic peptides entered a new registration cycle in 2026, that different peptide substances share one tonnage threshold, or that a shipment is guaranteed to clear customs. Before a transaction, verify the current consolidated rules, applicable amendments and substance-specific requirements with the responsible regulatory specialist. Product identity and supply-chain facts determine the next questions. [1]

Distinguish the substance from the supplied preparation

Record the exact chemical identity, composition, concentration and relevant identifiers of the proposed material. A peptide name, trade-name comparison or INCI description may not be enough for the legal substance identity. Ask about salts, counter-ions, complexation and constituents where they affect the assessment. For a solution or blend, identify the substances rather than treating the mixture as a single invented registration identity. Avoid deciding that every peptide is a polymer, exempt, or identical to another sequence solely from a broad ingredient category. The legal assessment must follow the actual material.

Map the legal entities and import route

Identify the non-EU supplier, EU/EEA importing entity and the party responsible for the relevant REACH duties. A purchase-order address, broker, delivery term or warehouse location does not alone answer who has the importer role. Article 8 provides a route for a qualifying non-Community manufacturer, mixture formulator or article producer to appoint an only representative established in the Community. Where that route is used, verify who is covered and for which substances and supply volumes. A vague statement that a supplier “has REACH” cannot replace confirmation of the actual coverage. [1]

Keep ingredient import and finished-cosmetic duties separate

Article 6 sets out the general registration obligation for a manufacturer or importer of a substance, on its own or in mixtures, at one tonne or more per year, subject to the regulation's applicable exceptions and conditions. Article 2(6)(b) addresses the Title IV treatment of cosmetic mixtures in the finished state intended for the final user; it is not a general exemption for all cosmetic raw materials from REACH. Separately, Article 10 of Regulation 1223/2009 requires the cosmetic safety assessment before a product is placed on the market. Neither registration nor an SDS substitutes for that finished-product process. [1] [2]

Selection criteria: evaluate tonnage, coverage and documents

Calculate tonnage by the relevant substance and entity

Begin with the substances in the material and the responsible entity's relevant annual quantities. The one-tonne threshold is not a generic quota shared across every chemically different peptide SKU. Conversely, different preparations containing the same substance require a substance-aware review rather than independent product-code assumptions. As an arithmetic illustration only, 2,000 kg of a preparation documented as 1% of a defined substance by mass contains 20 kg of that substance. This does not decide the legal annual tonnage, registration coverage or exemption: other imports and applicable calculation rules must also be assessed. [1]

Check the statement against the supply chain

Request the substance identity used for the regulatory assessment, the party making the statement and the basis of claimed registration coverage or exemption. Where an only representative is involved, ask for confirmation applicable to the importing entity, substance and relevant quantities through the proposed chain. Have the competent reviewer examine ambiguities rather than guessing from a registration number or a generic declaration. The same supplier may offer different grades, compositions or supply routes. A statement for one material or transaction does not automatically cover another preparation, a different importer or increased volume.

Separate analytical, hazard and regulatory evidence

A lot COA supports review of stated analytical results and identity checks; it is not a REACH registration or a complete regulatory dossier. An SDS supplies applicable hazard and safe-handling information and must describe the actual substance or mixture. A TDS explains technical characteristics and processing. Regulation 2020/878 sets out requirements for the compilation of SDS under REACH Annex II. Verify applicability, revision, composition and language requirements with the responsible reviewer rather than treating any English PDF as sufficient everywhere. The three documents serve different decisions, and none alone authorizes every possible import or cosmetic claim. [3]

Apply the identity questions to real catalog examples

For Copper Peptide GHK-Cu, confirm the offered complex identity, full supplied composition and the analytical basis behind copper and peptide figures; do not substitute a generic peptide description. For Palmitoyl Tripeptide-1 and Acetyl Hexapeptide-8, establish whether the offer is a powder or carrier-containing preparation. For the Matrixyl 3000-type peptide blend, request each constituent and its amount. Trade-name comparison does not establish branded origin, legal identity, registration or interchangeability. These catalog links are examples of document requests, not certificates of regulatory status.

Three questions that need different evidence

Question Relevant evidence Insufficient shortcut
Does the lot match its specification?Lot COA, identity and agreed testsGeneric catalog purity
Are the import duties addressed?Substance/entity/quantity assessment and applicable coverage“REACH compliant” without scope
Can the finished cosmetic be marketed?Product-specific cosmetic safety and other applicable requirementsRegistration or SDS alone

Practical recommendation: create a transaction-specific approval file

Make unresolved issues visible before ordering

Create a register with the material and composition version, substance identity, supplier, importing entity, route, annual-quantity basis, claimed coverage or exemption, supporting document, reviewer and outstanding questions. Hold the decision if a critical identity or coverage question remains unresolved. Record what evidence was requested and what answer was received. A positive analytical sample result cannot close a missing regulatory-role assessment, just as an administrative statement cannot establish formula compatibility. Keep the scope of each approval explicit so it can be rechecked when a source, carrier or importing entity changes.

Check restrictions and destination use independently

Registration is not the same as unrestricted use or official endorsement of cosmetic efficacy. Review any applicable restrictions, authorisation-related obligations and classification or communication requirements for the exact material and use. Article 67 concerns restrictions under Annex XVII, with the scope qualification in Article 67(2) for cosmetic uses regarding restrictions addressing human-health risks within the cosmetics legislation. Check whether a particular restriction applies to the material and use; registration does not settle that question. Separately assess the cosmetic formula, exposure, ingredient conditions and intended claims for the destination market. Do not infer EU cosmetic acceptability merely because a raw material appears in a catalog, has an INCI name or passed an incoming assay. A substance-specific review is essential. [1] [2]

Assess logistics without turning delivery terms into legal cover

Confirm packaging, storage, transport documentation, availability and delivery terms for the actual order, alongside the regulatory review. DDP, bonded storage or stock already located in Europe may change commercial responsibilities or logistics, but the label alone does not prove who holds all REACH duties, which quantities are covered or that customs will raise no questions. Require the proposed route and responsible entities to be named. This briefing makes no time-saving, clearance-time or inventory claim for RAWESS; those facts need order-specific confirmation and records rather than an assumed warehouse narrative.

Maintain the file and the product-development evidence

Set an owner and review trigger for changes in substance identity, composition, supplier, only representative, importer, volume or applicable law. Keep regulatory decisions separate from the lot-release and formulation records but cross-reference them. Use the peptide supply-form comparison and active-concentration calculation guide for technical questions, and the document comparison for requests. Download the English product guides to prepare a brief; request current regulatory statements for the actual supply chain before relying on them for a commercial decision.

Summary and next step

Approve the transaction by substance, entity, quantity and use. A peptide catalog page helps define the material; analytical, regulatory and finished-product evidence must then answer their own questions.

Download product guides (English) →

References and data summary

This is an editorial interpretation of identified provisions, reviewed on 1 November 2026, not a claim that a new universal peptide law took effect that day. Check current consolidated law for the transaction.

Read and checked: 1 November 2026

  1. [1] Regulation (EC) 1907/2006 — REACH, Articles 2(6)(b), 6, 8 and 67. Source version / publication: 2026-06-22.

    Regulation 1907/2006: Article 6(1), general registration threshold; Article 8, only representative; Article 2(6)(b), scope of Title IV for finished cosmetic mixtures; Article 67, restrictions. One tonne or more per year applies in the stated substance/entity framework, subject to applicable exceptions. It is not one common threshold for all different peptides or proof of coverage for a RAWESS shipment.

  2. [2] Regulation (EC) 1223/2009 — Article 10 and Annex I. Source version / publication: 2026-05-18.

    Regulation 1223/2009, Article 10 and Annex I: cosmetic safety assessment and its information requirements. Ingredient registration or a supplier document does not replace the assessment of the complete cosmetic.

  3. [3] Regulation (EU) 2020/878 — requirements for safety data sheets. Source version / publication: 2020-06-18.

    Regulation 2020/878, Annex: compilation requirements for SDS under REACH Annex II. Document structure and content requirements are distinct from deciding whether a particular SDS or import arrangement is sufficient.

Data and calculation notes

Legal quantity cited: one tonne or more per year under Article 6(1), not a blanket exemption below it from every REACH duty. Teaching example: 2,000 kg × 1% = 20 kg of a defined constituent; this is not a RAWESS volume, legal tonnage determination or registration certificate. No new 2026 deadline, market-growth statistic or customs lead-time estimate is asserted.

Product evidence used in this article